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ABSTRACT:
Background: Previous studies have found specific soy isoflavones (Genistein, Daidzein,
Glycitein) demonstrate anti-tumor properties against several cancer types, including oral cancer.
Few studies have evaluated whole soy extract, containing a combination of these isoflavones and
other bioreactive compounds, which may function synergistically and more effectively against
oral cancers. Preliminary work by this group has now demonstrated whole soy protein extract
(SPE) inhibits oral cancer cell growth specifically and selectively, through independent cellcycle and apoptotic pathways. However, more recent evidence now suggests that ingestion of
vitamin D3, either in dietary foods or supplements may potentiate the activity of soy components
and their anti-tumor effects.
Objective: The primary goal of this study was to investigate the interactive and inter-connected
effects of 1, 25-dihydroxyvitamin D3 administration with the anti-proliferative effects of whole
soy protein extract (SPE) on oral cancer and normal cell lines in vitro.
Methods: Three oral squamous cell carcinoma cell lines (SCC15, SCC25, and CAL27) were
treated with 1, 25-dihydroxy Vitamin D3 at physiological concentrations (10-125 nmol). Cell
growth was then compared with cell treatment using soy protein extract (SPE) within the normal
physiologic range (0 - 10 /L). Interactive effects were then evaluated using co-administration
of SPE and 1, 25-dihydroxy Vitamin D3. Quantitative RT-PCR was performed at various time
points to determine any changes in mRNA expression for key cell cycle and apoptotic signaling
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pathway regulators, including p53, c-myc, ornithine decarboxylase (ODC), caspase-2, caspase8, and bax.
Results: Administration of 1, 25-dihydroxy Vitamin D3 induced distinct dose-dependent,
growth-inhibitory effects in all three oral cancer cell lines examined. These inhibitory effects
were comparable to the overall range of growth inhibition induced by SPE. However, the
combined effects of co-administration were far greater, suggesting the presence of synergistic
relationships between these components. In addition, these results indicate that either treatment
alone appeared to modulate mRNA expression of oral cancer cell-cycle promoters c-myc and
ODC, as well as the caspase-dependent apoptosis pathway, while only 1, 25-dihydroxy Vitamin
D3 administration appeared to influence the bax pathway.
Conclusion: These results suggest that co-administration with 1, 25-dihydroxy Vitamin D3 and
SPE may enhance their anti-tumor effects. This study may help to explain, in part, why balanced
diets rich in fruits, vegetables, and soy protein, are associated with protection against
development and progression of oral cancers, although further study is needed to develop
specific public health recommendations for oral cancer treatment and prevention.
Key words: vitamin D, soy extract, whole soy protein, oral cancer, growth inhibition.

BACKGROUND:
Oral cancer: The main risk factors contributing to the development of oral cancers in the United
States (US) are tobacco use (in the form of smoking), and alcohol consumption, which together
may be responsible for up to 80% of this cancer risk [1-3]. Another important risk factor for oral
and pharyngeal cancers (OPC) is infection with the human papillomavirus (HPV), which has
been identified in a significant subset of these cancers [4, 5]. More recently, evidence has
demonstrated that dietary intake may account for as much as 20-25% of the variability in OCP
risk, with health-protective effects and reduced incidences associated with specific dietary
components such as fruits and vegetables, soy proteins, coffee, fiber, folic acid, and the vitamins
A, C, D, and E [6, 7].
Diet and nutrition: In addition to these health protective and cancer preventive effects, evidence
now suggests that progression of oral cancer is also intricately linked with diet and nutrition,
which can modulate the influence of all three major oral cancer risk factors, as well as cellular
growth [8]. For example, dietary fruit or vegetable intake separately and independently reduces
oral cancer risk or progression - even after adjusting for age, gender, or tobacco use and alcohol
consumption [8, 9]. The efforts to identify and characterize specific dietary components with
these potent chemo preventive and chemotherapeutic properties have led researchers to explore a
large number of putative anti-cancer agents derived specifically from fruits, vegetables and
legumes.
Oral
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glucosinolates, indoles, isothiocyanates, protease inhibitors, plant sterols, allium compounds,
limonenes, selenium, vitamin C, vitamin E, and dietary fiber all have noted inhibitory effects on
oral cancer [10-12]. The majority of studies focusing on dietary prevention and therapy for oral
cancer have explored the role of flavonoids, part of a large family of polyphenolic compounds
made by plants [13-19]. New evidence, however, has suggested that another subclass of
flavonoids highly concentrated in soybeans and soy-containing foods (isoflavones) may also
exhibit potent effects specific for oral cancers [20-24].
Soy isoflavones: Many of these studies have focused on specific isoflavones derived from soy,
which include Daidzein, Genistein, and Glycitein, which are capable of inhibiting growth and
proliferation of oral cancers [25-27]. Although significant, these effects were observed in vitro at
supraphysiologic levels (> 10 mol/L), which may be neither safe (in vivo) nor feasible through
dietary consumption or nutritional supplementation. This group was among the first to
demonstrate that soy proteins, in combination, may be useful and effective against oral cancers at
concentrations that approximate physiologic serum levels (0-2 mol/L) achievable through
dietary or supplement intake, which may help to explain why diets rich in fruits, vegetables, and
soy protein are associated with protection against development and progression of oral cancers
[24]. There is some evidence suggesting that synergistic effects of multiple isoflavones in whole
soy foods and soy extracts may be responsible for preventing the negative side effects observed
with single agent administration to normal cells, as well as the expression of anti-cancer effects
at much lower serum concentrations [28, 29].
Soy interactions with Vitamin D3: Researchers have focused on the direct, antitumor
properties of soy isoflavones on oral cancers; however, few studies have evaluated the interactive
effect of whole soy (or soy-derived isoflavones) via regulation of P450 enzymes, involved in the
metabolism of Vitamin D. However, there is evidence to suggest this may be a significant
regulatory pathway of anti-cancer action as the few studies completed to date have demonstrated
that soy protein (both in vivo and in vitro) directly influences the expression of P450 enzymes in
other cancers - thereby regulating cellular Vitamin D metabolism [30-32]. For example, CYP24
is often highly expressed in many cancers, which degrades newly synthesized or serum-derived
levels of 1, 25-dihydroxyvitamin D3 [33-36]. These studies suggest that dietary intake of soy
may result in a consistent down-regulation of CYP24, thereby enabling the functions and anticancer properties of Vitamin D [32, 37].
Vitamin D and oral cancer: Consistent with these laboratory findings, large-scale population
studies clearly demonstrated that low serum vitamin D levels and vitamin D deficiencies are
associated with much higher cancer risk [38, 39]. More specifically, epidemiologic and casecontrolled studies have confirmed that low vitamin D levels and deficiency are strongly
associated with OPC risk [40, 41]. The primary mechanism of Vitamin D action is mediated
through binding of either 1, 25(OH)2D (active form) or 25(OH)D (less active form) to the
vitamin D receptor (VDR), which is a member of the nuclear receptor super family of steroid and
thyroid hormones with gene regulatory and consequent anti-proliferative properties [42, 43].

Functional Foods in Health and Disease 2013; 3(6):183-202

Page 186 of 202

Vitamin D mechanism: Binding of 1, 25(OH)2D to the VDR (either in the cell nucleus or
cytoplasm) promotes association of the VDR- 1,25(OH)2D complex with the retinoid X receptor
(RXR) [41, 42]. The 1, 25(OH)2D–VDR–RXR complex binds to vitamin D-response elements
in DNA which operate to initiate gene transcription. Activation of the VDR by 1, 25(OH)2D can
restore or enhance pro-apoptotic effects in different cancer cells through transcriptional
activation of bax and p-calpain, two effective pro-apoptotic proteins [44, 45]. Although much is
known about these effects in other cancers, few studies to date have evaluated Vitamin D in oral
cancers [46, 47].
Evidence for interactive effects: There is now evidence that many oral cancers may, in fact,
exert their effects on cellular Vitamin D metabolism by changing the availability of (or affecting
the ability to bind to) the VDR. New evidence demonstrates that some oral cancers may exhibit
reduced VDR expression [48, 49]. In addition, Ras activation (common in many oral cancers)
might also impair Vitamin D-mediated transcription. Cytochrome p450 (CYP24, the enzyme
responsible for degrading vitamin D) exhibited the highest up-regulation (196-fold increase)
from a screening of more than 4,500 genes in one oral cancer cell line [47]. This may provide
some evidence consistent with the observation that CYP24 mutations may lower oral cancer risk
compared with wild type, after adjusting for age, gender, alcohol consumption, and smoking
status [50].
Based upon this information, the overall objective of this study is to evaluate the anticancer properties of soy protein extract (SPE), which is available as a dietary supplement and
most closely resembles the whole soy food that most US adults are likely to consume. The
effects of SPE against well-characterized oral cancer cell lines will be evaluated using in vitro
analysis methods. These experiments will be performed in conjunction with administration of
Vitamin D to determine the interactive effects of SPE on Vitamin D-induced oral cancer growth
inhibition.
Based upon previous work that determined SPE and Vitamin D are each, independently
sufficient to mediate the proliferative phenotypes of these cancers in this experimental model, the
working hypothesis is that co-administration will synergistically amplify these effects. Using in
vitro analysis methods, any quantitative differences in viability and growth of oral cancer cells
will be measured. The specific aims will be to characterize the inhibition of oral cancer
proliferation induced by SPE administration in combination with Vitamin D, as well as any
effects on cellular viability. The activation and expression of the apoptotic regulators, caspase-2,
caspase-8, and bax, will also be assessed.
MATERIALS AND METHODS:
Cell culture and cell lines: The human oral squamous cell carcinoma cell lines, CAL 27 (CRL2095) and SCC25 (CRL-1628), were obtained from American Type Culture Collection (ATCC:
Manassas, VA). CAL 27 cells were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) with 4.0 mM L-Glutamine adjusted to contain 3.7 g/L sodium bicarbonate, 4.5 g/L
glucose, and 110 mg/L sodium pyruvate, obtained from HyClone (Logan, UT). SCC25 cells
were maintained in a 1:1 mixture of DMEM and Ham’s F12 medium with 2.5 mM L-Glutamine,
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modified to contain 15 mM 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES), 0.5 mM
sodium pyruvate, and 1.2 g/L sodium bicarbonate.
The normal oral gingival fibroblast cell line, HGF-1 (CRL-2014), was also obtained from
American Type Culture Collection (ATCC: Manassas, VA). HGF-1 cells were maintained in
DMEM with 4 mM L-Glutamine, adjusted to contain 3.7 g/L sodium bicarbonate and 4.5 g/L
glucose, from HyClone (Logan, UT). All cell culture media was supplemented with 1%
Penicillin (10,000 units/mL)-Streptomycin (10,000 g/mL) solution and 10% fetal bovine serum
(FBS) obtained from HyClone (Logan, UT). Cells were cultured in 75 cm2 BD Falcon tissueculture treated flasks (Bedford, MA) at 37°C and 5% CO2 in humidified chambers.
Materials: 1, 25-dihydroxyvitamin D 3 (VitD3) was obtained from GNC Preventive Nutrition®
(Pittsburgh, PA). Proliferation and viability assays were performed in the appropriate complete
media, with and without the addition of VitD3 (10, 50 and 125 nmol). This concentration range
(25 – 312.5 ng/mL) approximates the physiologic concentrations of the less active form of VitD3,
but supraphysiologic concentrations of the active form, which allowed for short-term in vitro
effects to be observed [42, 51]. This also enabled comparison with the only other studies
examining OPC cell lines [46, 47], which utilized similar concentration ranges (1, 10, 100 nmol
or 2.5, 125, 250 ng/mL).
Soy protein extract (SPE) was obtained from GNC Preventive Nutrition® (Pittsburgh, PA).
Equivalent amounts of SPE were used to approximate the low- (10 g/mL), mid- (50 g/mL),
and high-range (100 g/mL) concentrations of flavonoid extracts utilized in prior in vitro studies
[16, 17, 19], which were 10, 50, and 100 g/mL. In addition to total SPE, the concentration of
soy isoflavones for each experimental condition was also calculated to determine if these
concentrations were within the normal physiologic range (0 - 10 /L).
Quantitative analysis provided by GNC demonstrated each gram of SPE contained 0.86 –
2.6 mg of isoflavones, with 0.30-0.91mg/g Daidzein (all forms), 0.52-1.56 mg/g Genistein (all
forms), and 0.04-0.13mg/g Glycitein (all forms), resulting in an approximate ratio of 7:12:1
(Daidzein, Genistein, Glycitein, respectively). The proportional molecular weights (MW) of the
soy isoflavones in the SPE were calculated to be:
Daidzein (MW = 254.24) x 7 = 1779.68
Genistein (MW = 270.2) x 12 = 3242.40
Glycitein (MW = 284.24) x 1 = 284.24
Total (sum)
= 5306.32 / 20 = proportional, averaged MW 265.31
To derive physiologic concentration, the total amount of SPE used (mg/L) is multiplied by
the percentage of isoflavones contained within this amount; the proportional amount of total
isoflavone is then divided by the averaged MW to yield moles (M/L); this amount is converted to
derive final isoflavone concentration (mol/L) as follows:
10 g/mL SPE = 10 mg/L or 0.01 g SPE
0.01 g SPE (0.0026 isoflavone concentration per g/SPE) = 0.000026 g total isoflavone
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0.000026 g / 265.31 MW = 0.00000000979 mol/L (1,000,000) = 0.0979 mol/L
10 g/mL SPE = 0.0979 mol/L total isoflavone
=
50 g/mL SPE = 0.4895 mol/L L total isoflavone =
100 g/mL SPE = 0.979 mol/L total isoflavone
=

approximately 0.1mol/L
approximately 0.5mol/L
approximately 1.0 mol/L

Previous studies have demonstrated normal physiological levels of total plasma soy
isoflavones vary between 1 and 2 mol/L [52, 53], although higher concentrations have been
observed among Asian populations [54, 55]. Based upon this information, the range of soy
isoflavone concentrations utilized in this study (0.1 – 1.0 mol/L) was within the normal
physiologic range. The individual concentrations for the active soy isoflavones are as follows:

SPE
Daidzein
Genistein
Glycitein

10 g/mL
2 M/L
0.0357 M/L
0.057 M/L
0.005 M/L

50 g/mL
10 M/L
0.185 M/L 
0.289 M/L 
0.023 M/L 

100 g/mL
20 M/L
M/L
M/L
M/L

Proliferation: Proliferation assays were performed in the appropriate complete media, with and
without the addition of SPE, VitD3 or both, prior to the start of each experimental assay. In brief,
cells were plated in Corning Costar high-throughput, 96-well assay plates (Corning, NY) at a
concentration of 1.2 x 104 cells per well, which roughly approximates 30-40% confluence per
well at the onset of each assay. Proliferation was subsequently measured after three days.
Cultured cells were fixed after 72 hours or day 3 using 50 L of 10% buffered formalin, and
were stained with crystal violet 1% aqueous solution (Fisher Scientific: Fair Lawn, NJ). The
relative absorbance was measured at 630 nm using a Bio-Tek ELx808 microplate reader
(Winooski, VT). Data was analyzed and graphed using Microsoft Excel (Redmond, WA) and
SPSS (Chicago, IL). Three separate, independent replications of each experiment were
performed.
Statistics: Comparisons of the effects of treatments were made using two-tailed t-tests with α =
.05. All samples were analyzed using two-tailed t-tests as departure from normality can make
more of a difference in a one-tailed than in a two-tailed t test [56]. As long as the sample size is
moderate (> 20) for each group, quite severe departures from normality make little practical
difference in the conclusions reached from these analyses. Multiple analyses involving twosample t-tests have higher probability of Type I errors, leading to false rejection of the null
hypothesis (H0). To confirm the effects of these experiments, one-way analysis of variance
(ANOVA) was used to assess statistical significance, p <0.05. In addition, the data were
analyzed after each experimental set to determine whether if the growth inhibition was normally
distributed. This analysis revealed the cumulative probably of these data falling within a normal
distribution was 0.99379 or 99.38% (= 0.0125). Because the outcome measures were tested
against a three (individual tests of SPE or VitD3concentration) or four (combination of SPE and
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VitD3 concentrations) predictors, a Bonferroni-adjusted significance level of  = 0.0125 was
used to account for the increased possibility of type I error ( = 0.05 / 4 = 0.0125).
Survival and viability: Prior to plating cells for proliferation assays, aliquots of trypsinized cells
were stained using Trypan Blue (Sigma: St. Louis, MO), and live cells were enumerated by
counting the number of Trypan-blue negative cells using a VWR Scientific Counting Chamber
(Plainfield, NJ) and a Zeiss Axiovert 40 inverted microscope (Gottingen, Germany). At each
time point (d1-d3), several wells were processed using the Trypan stain, and live cells were
enumerated using this procedure.
RT-PCR: RNA was isolated from 1.5 x 107 CAL27, SCC25 and SCC15 cells at baseline (day
0), after 24 hours (day 1), and 72 hours (day 3) following administration of VitD3 combined with
SPE at the indicated concentrations; lowest concentration [L] and the Growth Inhibitory
Maximum (GIMAX) or highest [H] concentration using ABgene Total RNA Isolation Reagent
(Epsom, Surrey, UK) and the procedure recommended by the manufacturer. RT-PCR was
performed on total RNA with the ABgene Reverse-iT One-Step RT-PCR Kit (ReadyMix
Version) and a Mastercycler gradient thermocycler (Eppendorf: Hamburg, Germany). The
following mRNA primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [17], p53
[17], c-myc [8], ornithine decarboxylase (ODC) [57], caspase-2 [58], caspase-8 [59], and bax
[58], synthesized by SeqWright (Houston, TX), were used:
p53 forward primer, ACCAGGGCAGCTACGGTTTC;
p53 reverse primer, CCTGGGCATCCTTGAGTTCC;
c-myc forward primer, TCCAGCTTGTACCTGCAGGATCTGA;
c-myc reverse primer, CCTCCAGCAGAAGGTGATCCAGACT;
ODC forward primer, AATCAACCCAGCGTTGGACAA;
ODC reverse primer, ACATCACATAGTAGATCGTCG;
caspase-2 forward primer, TGGCATATAGGTTGCAGTCTCGG;
caspase-2 reverse primer, TGTTCTGTAGGCTTGGGCAGTTG;
caspase-8 forward primer, GATATTGGGGAACAACTGGAC;
caspase-8 reverse primer, CATGTCATCATCCAGTTTGCA;
bax forward primer, GGTTTCATCCAGGATCGAGACGG;
bax reverse primer, ACAAAGATGGTCACGGTCTGCC;
GAPDH FORWARD:
ATCTTCCAGGAGCGAGATCC;
GAPDH REVERSE:
ACCACTGACACGTTGGCAGT;
RNA standard: GAPDH was obtained from control cells, human gingival fibroblasts (HGF-1)
0.3-0.5 x 106 cells/mL were used to establish the minimum threshold (CT) and saturation (CS)
cycles required for calibration and concentration comparisons using relative endpoint (RE) RTPCR. GAPDH signal detection above background or threshold (CT) required a minimum of ten
cycles (C10), with saturation (CS) observed at C40. Based upon this data, RE-PCR was
performed at C35, above the lower detection limit but below the saturation limit.
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In brief, one (1) g of template (total) RNA was used for each reaction. The reverse
transcription step ran for 30 minutes at 47°C, followed by denaturation for 2 minutes at 94°C.
Thirty-five amplification cycles were ran, consisting of 20 second denaturation at 94°C, 30
seconds of annealing at 58°C, and 6.5 minutes of extension at 72°C. Final extension was run for
5 minutes at 72°C. Reaction products were separated by gel electrophoresis using Reliant 4%
NuSieve® 3:1 Plus Agarose gels (Lonza: Rockland, ME). Bands were visualized by UV
illumination of ethidium-bromide (EtBr)-stained gels and captured using a Kodak Gel Logic 100
Imaging System and 1D Image Analysis Software (Eastman Kodak: Rochester, NY).
Quantification of RT-PCR band densitometry was performed using Adobe (San Jose, CA)
Photoshop imaging software, Image Analysis tools.
RESULTS:
A dose-dependent response relationship between growth inhibition and VitD3 administration was
observed in all three oral squamous cell carcinoma cell lines (CAL27, SCC25, SCC15) with
increasing concentrations resulting in more robust inhibition of cellular proliferation (Figure 1).
For example, the lowest concentration VitD3 (10 nmol or 2.5 ng/mL) reduced growth
significantly (compared with baseline controls) by 11%, 6.5%, and 12% in CAL27, SCC25, and
SCC15 cells (p<0.05), respectively. Higher concentrations of VitD3 (50 nmol or 125 ng/mL)
induced greater growth inhibition, reducing proliferation by 18.6%, 38.8%, and 18.2%,
respectively (p<0.01). The highest concentration (125 nmol or 312.5 ng/mL) induced the greatest
effects, inhibiting proliferation by 29.1%, 43.1%, and 32.1%, respectively – which was
determined to be the observed growth inhibitory maximum (GIMAX) concentration. Higher
concentrations induced ever-diminishing effects above this concentration 150 – 300 nmol or 375
-750 ng/mL (data not shown), which approximate physiologic levels of vitamin D intoxication
[51].
Growth inhibition was also observed following SPE administration among all three cell
lines, although these effects were not uniform. More specifically, the lowest concentration of
SPE (10 g/mL or 2 M/L) was sufficient to inhibit growth significantly by 25.8%, 20.2%, and
15.2% in CAL27, SCC25, SCC15 cells, respectively (p<0.05). The growth inhibitory maximum
(GIMAX) concentration of SPE was observed at 50 g/mL (10 M/L), which inhibited growth by
39.1%, 29.2%, and 19.2% in CAL27, SCC25, SCC15 cells, respectively (p<0.01). However, the
highest concentration evaluated (100 g/mL or 20 M/L) was not sufficient to inhibit CAL27
growth as intensely (-31.3%, p<0.01) and the effects on SCC25 and SCC15 were
indistinguishable from those observed at 50 g/mL (p>0.05). No greater effects were observed
above this concentration range.
To assess any additive, interactive or synergistic effects, three-day growth assays were
performed using of concomitant administration of VitD3 and SPE combining the lowest [L] and
the highest [H] GIMAX concentrations (Figure 2). For example, the combined effects of the lowest
concentrations of VitD3 [L] and SPE [L] inhibited growth of all three cell lines more intensely
than either component independently. This combination inhibited CAL27 growth by 41.8%,
which is greater than the effects of VitD3 [L] or SPE [L] individually (-18.6%, 25.8%,
respectively). This combination resulted in similar growth inhibition among SCC15 cells (-
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31.2%), which was stronger than either in isolation (-18.2%, 15.2%, respectively). However, this
combination precipitated equivalent reductions (-37.1%) to VitD3 [L] (-38.8%) in SCC25 cell
growth, although this was more than what was observed under SPE [L] administration (-29.1%).
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Figure 1. Oral cancer proliferation inhibition by VitD3, or SPE administration. (A) Three day
growth of CAL27 was significantly inhibited by increasing concentrations of VitD3 (10 nmol, -11%; 50 nmol, 18.6%, 125 nmol, -29.1%) and SPE (10 nmol, -25.8%; 50 nmol, -39.1%; 100 nmol, -31.3%) compared with baseline
controls. (B) SCC25 growth was also inhibited by VitD 3 (10 nmol, -6.5%; 50 nmol, -38.8%, 125 nmol, -43.1%) and
SPE (10 nmol, -20.2%; 50 nmol, -29.2%; 100 nmol, -28.1%). (C) SCC15 inhibition by VitD3 (10 nmol, -12%; 50
nmol, -18.2%, 125 nmol, -32.1%) and SPE (10 nmol, -15.2%; 50 nmol, -19.2%; 100 nmol, -19.1%) was similar.
Note: * denotes growth inhibitory maximum (GI MAX).

Higher concentrations of SPE were then evaluated in combination with low-dose VitD3 to
ascertain any differential effects on cellular growth inhibition. Although the combination of
VitD3 [L] and SPE [H] reduced growth in all three cell lines, this inhibition was nearly
equivalent to the effects observed with VitD3 [L] and SPE [L]. In brief, CAL27 growth was
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inhibited by 41.5%, which was greater than the effects of VitD3 [L] (-18.6%) or SPE [H] (39.1%) alone, but indistinguishable from the results of the first combination trial (-41.8%,
p>0.5). A similar result was observed in SCC15 cells, which were inhibited by 33.2%, which
was consistent with the previous combination (-31.2%, p>0.5), but greater than either VitD3 [L]
(-18.2%) or SPE [H] (-19.2%) in isolation. The growth of SCC25 cells was not significantly
altered by the increased concentration of SPE (-32.1% versus -37.1%) and was similar to the
results with either VitD3 [L] (-38.8%) or SPE [H] (-29.2%) alone.
Interestingly, when the GIMAX concentration of VitD3 [H] was combined with the GIMAX
concentration of SPE [H], growth was nearly completely inhibited. Growth in CAL27 cells was
inhibited by 83.1%, by 80.1% in SCC15 cells, and by 81.2% in SCC25 cells. These effects were
significantly greater than any other combination or single treatment evaluated for all three cell
lines (p < 0.01). Finally, each combination and the GIMAX concentrations for each variable were
tested on the normal oral gingival cell line (HGF-1), which exhibited no growth inhibition, but
rather stimulation of cell proliferation, which ranged between 18.2% and 41.2%.
To determine if the growth inhibitory effects of VitD3 or SPE administration on these cell
lines was due, at least in part, to alterations in cell survival or viability – each cell line and
experimental treatment was analyzed at each time point of the proliferation assays and the
viability assessed (Table 1). This analysis revealed that VitD3 and SPE administration was
sufficient to decrease viability among the oral cancer cell lines. More specifically, the baseline
viability of CAL27 cells (94.4%) was lowered by VitD3 [L] to 71.1% and more considerably by
VitD3 [H] to 50%. SCC25 (90.5%) and SCC15 (93.1%) viability was also diminished by VitD 3
[L] (72.3%, 68.2%) and more drastically by VitD3 [H] (53.1, 61.3%). Although SPE
administration was sufficient to reduce viability, these reductions were less dramatic and did not
differ significantly between the low- and the high-concentrations. For example, SPE
administration decreased CAL27 viability (94.4%) to 88.2% and 84.6% under SPE [L] and SPE
[H] administration, respectively. SCC25 and SCC15 viability was similarly reduced by the
addition of SPE [L] (85.2%, 84.7%) and SPE [H] (82.5%, 81.3%).
Table 1. Cell viability.
VitD3 [L] VitD3
[H]
CAL27
94.4%
71.1%
50.0%
SCC25
90.5%
72.3%
53.1%
SCC15
93.1%
68.2%
61.3%

CAL27
SCC25
SCC15

94.4%
90.5%
93.1%

SPE [L]

SPE [H]

88.2%
85.2%
84.7%

84.6%
82.5%
81.3%

VitD3 [L] VitD3 [L] VitD3
[H]
SPE [L]
SPE [H] SPE [L]

VitD3
[H]
SPE [H]

66.4%
67.1%
65.1%

23.4%
19.6%
14.9%

63.3%
62.6%
61.8%

48.2%
47.2%
51.3%
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The GIMAX concentration of VitD3 [H] was then combined with the low-dose of SPE [L],
which resulted in a significant change in growth inhibition in all three cell lines. CAL27 growth,
for example, was inhibited by 45.1%, which was greater than the inhibition observed under
either previous combination (-41.8% and -41.5%) or either alone (-29.1%, -39.1%). Similar
results were observed for SCC15 (-47.3%) and SCC25 (-53.2%), which was also greater than
either previous combination examined (SCC15: -31.2%, -33.2%; SCC25: -37.1%, -32.1%) or
VitD3 [H] (SCC15, -32.1%; SCC25, -43.1%) or SPE [L] (SCC15, -15.2%; SCC25, -29.1%).

HGF-1: +VitD3 [125]
HGF-1: + SPE [50]
HGF-1: +VitD3 [50] + SPE [10]
HGF-1: +VitD3 [50] + SPE [50]
HGF-1: +VitD3 [125] + SPE [10]
HGF-1: +VitD3 [125] + SPE [50]

CAL27: +VitD3 [125]
SCC25: +VitD3 [125]
SCC15: +VitD3 [125]
CAL27: + SPE [50]
SCC25: + SPE [50]
SCC15: + SPE [50]
CAL27: +VitD3 [50] + SPE [10]
SCC25: +VitD3 [50] + SPE [10]
SCC15: +VitD3 [50] + SPE [10]
CAL27: +VitD3 [50] + SPE [50]
SCC25: +VitD3 [50] + SPE [50]
SCC15: +VitD3 [50] + SPE [50]
CAL27: +VitD3 [125] + SPE [10]
SCC25: +VitD3 [125] + SPE [10]
SCC15: +VitD3 [125] + SPE [10]
CAL27: +VitD3 [125] + SPE [50]
SCC25: +VitD3 [125] + SPE [50]
SCC15: +VitD3 [125] + SPE [50]

VitD3 [H]

SPE [H]

VitD3 [L] + SPE [L]

VitD3 [L] + SPE [H]
VitD3 [H] + SPE [L]

VitD3 [H]
+ SPE [H]
-100

-80

-60

-40

-20

0

20

40

Figure 2. Effects of combined VitD3, and SPE administration on proliferation. The combined effect
of the lowest VitD3 [L] and SPE [L] concentrations inhibited CAL27, SCC25, and SCC15 growth by 41.8%, 37.1%,
and 31.2%. VitD3 [L] and the GIMAX concentration of SPE [H] inhibited CAL27, SCC25, and SCC15 growth by
41.5%, 32.1%, and 33.2%. The GIMAX concentration of VitD3 [H] combined with the low-dose of SPE [L] inhibited
CAL27, SCC25, and SCC15 growth by 45.1%, 53.2%, and 47.3%. The GI MAX concentrations of both VitD3 [H] and
SPE [H] inhibited growth more robustly in CAL27, SCC25, and SCC15 cells (-83.1%, -81.2%, and -80.1%).
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The combined administration of VitD3 and SPE had more variable effects. To illustrate, the
viability of CAL27, SCC25 and SCC15 was reduced under VitD3 [L] with either SPE [L]
(66.4%, 67.1%, 65.1%) or SPE [H] (63.3%, 62.6%, 61.8%) administration to levels that were
lower than either VitD3 or SPE alone (but were not dissimilar between these treatment groups).
However, the treatment with VitD3 [H] combined with SPE [L] dramatically reduced viability
among these three cell lines (48.2%, 47.2%, 51.3%). Furthermore, the combined treatment of
these cells with VitD3 [H] combined with and SPE [H] had more drastic effects on viability and
cell survival (23.4%, 19.6%, and 14.9%).
To determine if the growth inhibitory and viability reducing effects of VitD3 and SPE
administration were associated with differential gene expression, relative endpoint (RE) RT-PCR
was performed on total RNA isolated from each cell line following combination therapy using
oligonucleotide primers specific to the mRNA of critical apoptosis regulatory genes caspase-2
(an apoptosis initiator), caspase-8 (an apoptosis effector), and bax, as well as the cell-cycle
regulatory genes c-myc, ornithine decarboxylase (ODC) and the tumor suppressor, p53 (Figure
3). Three VitD3 - SPE combinations were evaluated due to their differential effects on growth, as
well as viability. These experimental conditions included VitD3 [L] - SPE [L], VitD3 [H] - SPE
[L], and VitD3 [H] - SPE [H]. This analysis revealed that the caspase initiator and effector,
caspase-2 and caspase-8 exhibited barely detectable mRNA expression under VitD3 [L] - SPE
[L] administration, although expression increased markedly under both VitD3 [H] - SPE [L] and
VitD3 [H] - SPE [H] administration. The expression of bax mRNA, which was easily observed in
all cell lines in every condition, also increased under all three experimental treatment conditions.

Figure 3. Relative endpoint RT-PCR analysis. Relative endpoint (RE) RT-PCR was performed on total
RNA extracted from CAL27, SCC25 and SCC15 cells under combination treatments of VitD 3 [L] - SPE [L], VitD3
[H] - SPE [L], and VitD3 [H] - SPE [H]. These treatments induced mRNA expression of all apoptosis-related genes,
caspase-2, caspase-8, and bax. The most marked changes in mRNA expression of cell-cycle related genes, c-myc
and ODC were observed under VitD3 [H] - SPE [H] administration.
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An analysis of the cell-cycle regulatory genes, c-myc, ODC and the tumor suppressor p53
revealed active mRNA expression in all three cell lines under VitD3 [L] - SPE [L]
administration. However, the increased administration of VitD3 [H] - SPE [L] and VitD3 [H] SPE [H] induced decreased expression of both c-myc and ODC. Interestingly, no observable
changes in mRNA expression of the tumor suppressor p53, which has been found to be actively
transcribed in all three cell lines, were observed except in SCC15 cells under the most
concentrated treatment condition: VitD3 [H] - SPE [H].
DISCUSSION:
The overall objective of this study was to evaluate the anti-cancer properties of soy protein
extract (SPE), which is available as a dietary supplement and most closely resembles the whole
soy food that most US adults are likely to consume as edamame, tofu, or other soy-based
products. The effects of SPE against well-characterized oral cancer cell lines were evaluated
using in vitro analysis methods in conjunction with administration of Vitamin D to determine the
interactive effects of SPE on Vitamin D-induced oral cancer growth inhibition. Based upon
previous work that determined SPE and Vitamin D are each, independently sufficient to mediate
the proliferative phenotypes of these cancers in this experimental model, the working hypothesis
was that co-administration would synergistically amplify these effects. These results of this study
clearly demonstrated these anti-tumor effects, which are consistent with previous reports and
observations. However, this may be the first study to evaluate the co-administration of SPE and
Vitamin D, as well as the first to report synergistic effects on growth inhibition of oral cancer
cell lines (under conditions of Vitamin D GIMAX concentrations).
Although this type of research has been extremely useful for identifying agents that are
now clinically demonstrated as effective agents against specific cancers, a number of limitations
must be considered when evaluating the outcomes of this study. First, one limitation of this and
other preclinical studies involves the use of oral cancer cell lines, as there may be underlying
dissimilar genetic mutations that might potentially influence the experimental outcomes. For
example, the SCC25 cell line has been found to contain a deletion in the cdk1 promoter that
contains a key transcriptional repressor region [60]. In addition, the CAL27 cell line contains a
nonsense mutation in the SMAD4 gene, while SCC15 cells were found to harbor a missense
mutation in SMAD2 - both signal TGF-β transduction proteins [61]. Finally, both CAL27 and
SCC15 cells contain a single nucleotide polymorphism in the S100A2 gene, a calcium-binding
tumor suppressor protein, although this does not appear to alter their propensity for growth,
migration or invasion [62]. However, a growing body of evidence demonstrates that deregulation
and reduced expression of key tumor suppressors, such as p16, in these cell lines may, in fact, be
the result of hyper methylation - providing further justification to elucidate the interconnected
roles of dietary components and transcriptional regulation in the growth and progression of oral
cancers [63-65].
Another limitation to be considered is that SPE, unlike Vitamin D, contains multiple
bioactive substances in addition to the soy isoflavones (Daidzein, Genistein, Glycitein), which
may have direct effects on cellular behaviors despite their relatively low concentrations [66, 67].
These SPE components include, but are not limited to, phytates (inositol hexaphosphate),
oligosaccharides, saponins, Kunitz inhibitor and Bowman-Birk Inhibitor (BBI) [68]. Some
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previous studies have demonstrated that saponins were capable of exerting growth inhibiting
effects on colon cancer cell lines in vitro [62, 69, 70]. In addition, other studies have
demonstrated cytotoxicity and apoptotic effects on oral cancers in vitro using saponins [71-73].
However, these effects in animal and human models may be severely limited due to low
absorption rates, as well as extremely low serum concentrations that are far lower than the
experimental concentrations that were evaluated [66, 67].
Finally, some recent studies have demonstrated there may be possible adverse effects of
elevated 25(OH)D concentrations on cancer risk in prostate, breast, pancreas, and esophageal
cancers, suggesting that these effects may depend on dose, timing and duration of exposure, as
well as tissue specific, lifestyle, and genetic factors [74, 75]. Although J- or U-shaped risk curves
have been proposed to describe the noted associations in these studies, confounding factors
present in the original studies are likely responsible for these findings [51, 74]. For example,
outcomes of intervention trials of supplemental Vitamin D were inconclusive due to the lack of
baseline vitamin D status reports of trial participants and consequent dose adequacy estimates
[51, 74, 75]. This may suggest that studies focused on the dose administered, rather than their
effect on alleviating deficiency, achieving adequacy, or adding to pre-trial adequate serum levels,
might have significantly affected the dose-response curves and further complicated the
interpretation of trial outcomes.
CONCLUSION:
Although many clinical studies have suggested Vitamin D status, intake, and supplementation
may have significant effects on oral cancer risk, progression, and mortality, growing
epidemiologic evidence now suggests that dietary patterns, which may include the intake of other
cancer preventing foods (such as soy) may influence these effects [1, 6]. This study is among the
first to examine the relationships between Vitamin D and soy administration in oral cancer cells,
which provides specific information about the mechanisms and pathways that may be modulated
along with growth inhibition and reduced viability. This study provides the first direct evidence
of the magnitude of these relationships, which may be particularly useful to oncologists, oral
health researchers, and nutrition epidemiologists as they analyze and develop rubrics for
generalizing the health protective effects of diet and dietary supplements, as well as the most
effective ancillary treatment options for patients with oral cancer.
List of abbreviations:
Soy protein extract (SPE); ornithine decarboxylase (ODC), United States (US), oral and
pharyngeal cancers (OPC), human papillomavirus (HPV), vitamin D receptor (VDR), retinoid X
receptor (RXR), Dulbecco’s Modified Eagle’s Medium (DMEM), 4-2-hydroxyethyl-1piperazineethanesulfonic acid (HEPES), fetal bovine serum (FBS), 1,25-dihydroxyvitamin D 3
(VitD3), molecular weights (MW), null hypothesis (H0), analysis of variance (ANOVA), lowest
concentration [L], growth Inhibitory Maximum (GIMAX), highest concentration [H],
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), human gingival fibroblasts (HGF-1),
minimum threshold cycle (CT), saturation cycle (CS), relative endpoint polymerase chain
reaction (RE) RT-PCR, ethidium-bromide (EtBr), Bowman-Birk Inhibitor (BBI).
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